Clinical Trials Logo

Waldenstrom's Macroglobulinaemia clinical trials

View clinical trials related to Waldenstrom's Macroglobulinaemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01592981 Completed - Clinical trials for Waldenstrom's Macroglobulinaemia

Randomised Trial in Waldenstrom's Macroglobulinaemia

R2W
Start date: January 2013
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to assess tolerability and efficacy of the Bortezomib, Cyclophosphamide and Rituximab combination as initial therapy for previously untreated patients with symptomatic Waldenstrom's macroglobulinaemia.